Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Events, Industry

18 Apr 2022

PsyCap Recap: Clearmind Medicine

With dozens of companies racing to drive classic psychedelics through clinical trials, or spending years and untold millions developing next-generation versions of these well-known molecules, Clearmind could have its own...

By Microdose

Industry

13 Apr 2022

Cybin Announces Positive Data on CYB004 DMT

Delivery of CYB004 via inhalation showed significant advantages over intravenously administered dimethyltryptamine (“IV DMT”) in preclinical studies...

By Microdose

Finance

1 Apr 2022

Mydecine Releases 2021 Financials and Announces Capital Raise

We're combining two announcements here....

By Microdose

Press Releases

31 Mar 2022

Albert Labs’ Files U.S. Patent Application for Production of Psilocybe Mycelia and other Fungi Species

Albert Labs’ culturing process can significantly increase the production volumes of psilocybin medicine...

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

23 Mar 2022

Filament Health Granted Second Patent

Filament has developed innovative technology to extract and standardize stable doses of natural compounds from magic mushrooms....

By Microdose

Industry

18 Mar 2022

A Closer Look at MindBio Therapeutics

So while ATAI and MindMed draw more eyeballs and investors to the sector, smaller firms like MindBio have the chance to do their early work while the wider industry grows...

By Microdose

Events

17 Mar 2022

LSD Conference Recap: IMIO Life

Dr....

By Microdose

Events

16 Mar 2022

LSD Conference Recap: MindBio Therapeutics

MindBio co-founder Justin Hanka kicked off the conference with a presentation during the “Emerging Treatments in Mental Health” panel....

By Microdose

Industry

16 Mar 2022

Novamind to Host MindMed’s Phase 2b Trial

Novamind will host the LSD Clinical Trial at its Draper, Utah research site, further strengthening its track record of hosting neuropsychiatry and psychedelic clinical trials....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.